



EUROPEAN COMMISSION
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

Health systems, medical products and innovation
Medical products: quality, safety, innovation



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

History of changes to the Compilation of Procedures

Date	Details
December 2003	First published by the European Medicines Agency on behalf of the Commission updating May 2001 version to include a new procedure for handling suspected quality defects, updated rapid alert procedure, addition of verification of validation to procedure and forms for exchange of information, and quality systems framework for EU inspectorates.
February 2004 (rev. 1)	Updated to include a new annex on investigational medicinal products to the procedure on the conduct of inspections together with a revised document on the training and qualifications of GMP inspectors. Both documents were developed in response to Art. 15(5) of Directive 2001/20/EC.
September 2004 (rev. 2)	Updated to include a minor change to section 5 on the procedure for handling rapid alerts and a consolidation of the procedure and various forms for the exchange of information. It includes a new form to be used in the event of an inspection performed in a third country with a negative outcome requiring co-ordinated administrative action throughout the Union.
February 2005 (rev. 3)	Revision to procedure on verification of GMP in third countries.
September 2005 (rev. 4)	<p>In accordance with Art. 47 of Directive 2004/27/EC and Art. 51 of Directive 2004/28/EC amending Directives 2001/83/EC and 2001/82/EC respectively, revised Union formats for a GMP inspection report and manufacturing authorisation and a Union format for a GMP certificate were introduced.</p> <p>Guidance to Competent Authorities was included on when inspections of active substance manufacturers may be appropriate based on the provisions of Art. 111(1) of Directive 2001/83/EC and Art. 80(1) of Directive 2001/82/EC as amended.</p> <p>A small change to appendix 2 of the summary report for inspections conducted at the request of the European Medicines Agency was also been introduced.</p> <p>The title of the procedure for handling suspected quality defects was corrected.</p>
July 2006 (rev. 5)	An introduction was added together with a minor change to the procedure on rapid alerts arising from quality defects as well as enhanced formats for the Manufacturing Authorisation and GMP Certificate.

September 2006 (rev. 5 reformatted)	The individual documents of the Compilation were reformatted and arranged in order to facilitate individual download from the website. No changes were made to the main texts of the documents.
October 2006 (rev. 6)	Inclusion of a procedure, applicable to centrally authorised products, for dealing with the delegation of the performance of a GMP inspection by the Supervisory Authority to another Competent Authority.
March 2007 (rev. 7)	A procedure for the issue and update of GMP certificates has been added. The Content of the fabricator's/manufacturer's batch certificate for drugs/medicinal products exported to countries under the scope of a Mutual Recognition Agreement, and the Activity/decision diagram for inspection findings for applications under the centralised system, have been removed.
April 2008 (rev 8)	The Quality System Framework for GMP Inspectorates was revised to introduce a quality risk management approach following the implementation of ICH Q9 guideline.
August 2008 (rev. 9)	Update to Training and Qualifications of GMP Inspectors document.
March 2010 (rev. 10)	A new procedure was added for dealing with serious GMP non-compliance, which is in addition also intended to ensure a coordinated response to CEP withdrawals or suspensions for non-GMP reasons. The procedures for handling suspected quality defects and Rapid Alerts have been updated to include active substances, falsified medicinal products and investigational medicinal products within their scopes. The GMP inspection report format has been revised in view of an agreement that additional summary reports, previously required for inspections requested by the European Medicines Agency, no longer need to be prepared.
August 2010 (rev. 11)	A new procedure Training and Qualifications of Inspectors performing GDP inspections was added together with an update to the introduction in view of the addition of the first document connected with GDP inspections being added. A revised document updating and extending the Procedure for Coordinating Foreign and Union Pre-Authorisation Inspections during the Assessment of Applications was published (Coordinating GMP Inspections for centrally authorised products). This allows for the removal of the Guideline on the Preparation of Reports on GMP Inspections Requested by either the CHMP or CVMP, in view of the introduction of the Union inspection report format in March 2010.
January 2011 (rev. 12)	A new procedure Training and Qualification of Inspectors Performing Inspections of Wholesale Distributors was added. The overall presentation of the Compilation was consolidated into a single document.

July 2011 (rev. 13)	Deletion of 'Exchange of Information on Manufacturers and Manufacturing or Wholesale Distribution Authorisations Between Competent Authorities in the European Economic Area' as agreed at the GMP/ GDP Inspectors Working Group (24-26/05/2011)
May 2012 (rev. 14)	New templates under the 'Forms used by regulators' section (Wholesale Distribution Authorisation, GDP certificates, GDP non-compliance statements) and a Registration of Manufacturer, Importer or Distributor of Active Substance (used in Medicinal Products for Human Use) template have been added to facilitate entry into the Union database as required by Directive 2011/62/EU. Procedure for Dealing with Serious GMP Non-Compliance Information Originating from Third Country Authorities or International Organisations has been added.
July 2012 (rev. 15)	The 'Union Format for Manufacturer's Authorisation' has been modified to facilitate harmonised interpretation. The 'Union Format for GMP certificate' has been similarly modified to facilitate interpretation and also to accommodate entry of inspected manufacturing operations for active substances. The 'Statement of Non-Compliance with GMP' and 'Notification of Serious GMP Non-Compliance Information Originating from Third Country Authorities or International Organisations' have been made stand-alone templates under the 'Forms used by regulators' section. A new template under the 'Forms used by regulators' section has been added: 'Request Form for the Exchange of Information on Marketing Authorisation Holders or Manufacturing Authorisation Holders between the Competent Authorities in the EEA'.
June 2013 (rev. 16)	<p>New documents added under the 'Procedures Related to GDP Inspections' section: GDP Inspection Procedure- Medicinal Products for Human Use, The Issue and Update of GDP Certificates- Medicinal Products for Human Use.</p> <p>A new section 'Interpretation Documents' has been created and an interpretation document for the Union format of a manufacturing/importation authorisation' has been included.</p> <p>The procedure 'A Model for Risk Based Inspection Planning of Pharmaceutical Manufacturers' (in the section 'Procedures Related to GMP Inspections') has been revised to incorporate the PI-037-1-PIC/S Recommended Model for Risk-based Inspection Planning in the GMP Environment.</p> <p>In the section 'Forms used by regulators', the template for 'GDP Inspection Format' has been added.</p>
October 2014 (rev. 17)	<p>The "Procedure for dealing with serious GMP non-compliance thus requiring co-ordinated measures to protect public or animal health" has</p> <p>replaced the "Procedure for Dealing with Serious GMP Non-compliance or</p> <p>Voiding/ Suspension of CEPs Thus Requiring Co-ordinated Administrative</p>

Action". The new procedure reflects the experience gained with the superseded procedure.

The "Guidance on the occasions when it is appropriate for competent authorities to conduct inspections at the premises of manufacturers, importers and distributors of active substances and manufacturers or importers of excipients used as starting materials" has been revised in order for it to be aligned with new requirements for medicinal products

Compilation of Union Procedures on Inspections and Exchange of Information

EMA/572454/2014 Page 253/253

for human use introduced by Directive 2011/62/EU.

July 2021 (rev. 18)

The Compilation has been restructured and split into two parts, Part I and Part II. Documents in Part I are Compilation procedures whereas Part II includes interpretation documents together with templates. The Introduction has been revised accordingly to reflect this change.

Furthermore, spelling and punctuation mistakes have been corrected throughout the whole document as well as some updates of terminology.

In addition, the following documents have been revised:

- Management of Reports of Suspected Quality Defects in Medicinal Products - The procedure was revised in order to provide more comprehensive guidance following quality risk management principles
- Management of Rapid Alerts Arising from Quality Defects Risk Assessment - The procedure was revised in order to provide more comprehensive guidance following quality risk management principles
- Procedure for dealing with serious GMP non-compliance requiring co-ordinated measures to protect public or animal health -Procedure has been revised as a result of experience with the superseded procedure; Appendix 6: Supervisory Risk Assessment has been updated.
- Outline of a Procedure for Co-ordinating the Verification of the GMP Status of Manufacturers in Third Countries
- A Model for Risk Based Planning for Inspections of Pharmaceutical Manufacturers
- Interpretation of the Union format for GMP certificate

	<ul style="list-style-type: none"> • Interpretation of the Union format for a wholesale distribution authorisation (medicinal products for human use) – new procedure • Union Format for a GMP Certificate • The issue and update of GMP certificates- minor update has been made primarily to align the procedure with experience. • Serious GMP Non-Compliance Info-from Third Countries or International Organisations • STATEMENT OF NON-COMPLIANCE WITH GMP Interpretation of the Union Format for Manufacturer/Importer Authorisation • Procedure for compliance management – new procedure
April 2022 (Rev 18 corrigendum)	a corrigendum of revision 18 of the Compilation of Union Procedures on Inspections and Exchange of Information (CoUP) to include 4 updated legal references which were overlooked with the publication of revision 18 of the CoUP
June 2023 (Rev 19)	Modifications were introduced through the revision 19 as a result of the entry into application of Regulation (EU) 2019/6 on veterinary medicinal products and repealing Directive 2001/82/EC and Regulation (EU) 2019/5 amending Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. A new procedure was added: EU/EEA Programme for Maintenance of Equivalence in Supervision of Good Manufacturing Practice (GMP) Compliance of Pharmaceutical Companies. A revision of the Union format for a wholesale distribution authorisation and interpretation document will be included in the upcoming revision.
September 2023 (Rev 19.1)	Minor modifications introduced to remove mention of repealed Directive 2003/94/EC and further minor editorial changes were introduced.
August 2024	In August 2024 Compilation of Union Procedures on Inspections and Exchange of Information (CoUP) was restructured from 1 document into single documents for every procedure/template. The updates for every procedure/template will be from now on recorded in each document published on EMA website.